Forme juridique Société à responsabilité limitée Siège social Numéro 19 Rue Route de Bastogne Code postal 9638 Localité Pommerloch Pays Luxembourg Parts détenues Nombre 131 000 Administrateur(s) / Gérant(s) Régime de signature statutaire Sous réserve de la Loi Luxembourgeoise et des présents Statuts, la Société est valablement engagée ou représentée à l'égard des tiers par : 10.1 si la Société a un Gérant Unique, la seule signature du Gérant Unique; 10.2 si la Société a plus d'un (1) Gérant, la signature unique de tout Gérant, à condition cependant que si des catégories différentes de Gérants (à savoir Gérant de catégorie A et Gérant de catégorie B) sont nommés, également la signature unique de tout Gérant (y compris par le biais de la représentation); 10.3 la signature unique de toute personne à qui un tel pouvoir aura été délégué conformément à l'Article 11. Kronimus Holger Hans Kronimus Holger Hans Nom Kronimus Prénom(s) Holger Hans Adresse privée ou professionnelle Numéro 2 Rue Adolf Dambach-Strasse Code postal 76571 Localité Gaggenau Pays Allemagne Type de mandat Organe conseil de gérance Fonction gérant Durée du mandat Date de nomination 04/07/2018 Durée du mandat Indéterminée Merklein Norbert Merklein Norbert Nom Merklein Prénom(s) Norbert Page 3 / 5 B226205 Adresse privée ou professionnelle Numéro 61 Rue Rothausstrasse Code postal 4132 Localité Muttenz Pays Suisse Type de mandat Organe conseil de gérance Fonction gérant Durée du mandat Date de nomination 18/01/2021 Durée du mandat Indéterminée Palm Christoph Palm Christoph Nom Palm Prénom(s) Christoph Adresse privée ou professionnelle Numéro 19 Rue route de Bastogne Code postal 9638 Localité Pommerloch Pays Luxembourg Type de mandat Organe conseil de gérance Fonction gérant Durée du mandat Date de nomination 04/07/2018 Durée du mandat Indéterminée Potoczny Zaneta Gabriela Potoczny Zaneta Gabriela Nom Potoczny Prénom(s) Zaneta Gabriela Adresse privée ou professionnelle Numéro 19 Rue route de Bastogne Code postal 9638 Localité Pommerloch Pays Luxembourg Type de mandat Organe conseil de gérance Fonction gérant Durée du mandat Date de nomination 27/02/2019 Durée du mandat Indéterminée Délégué(s) à la gestion journalière Régime de signature statutaire Sous réserve de la Loi Luxembourgeoise et des présents Statuts, la Société est valablement engagée ou représentée à l'égard des tiers par : 10.1 si la Société a un Gérant Unique, la seule signature du Gérant Unique; 10.2 si la Société a plus d'un (1) Gérant, la signature unique de tout Gérant, à condition cependant que si des catégories différentes de Gérants (à savoir Gérant de catégorie A et Gérant de catégorie B) sont nommés, également la signature unique de tout Gérant (y compris par le biais de la représentation); 10.3 la signature unique de toute personne à qui un tel pouvoir aura été délégué conformément à l'Article 11. Durée du mandat Date de nomination 05/07/2018 Durée du mandat Indéterminée Personne(s) chargée(s) du contrôle des comptes ERNST & YOUNG [2] ERNST & YOUNG N° d'immatriculation au RCS B47771 Dénomination ou raison sociale ERNST & YOUNG Forme juridique Société anonyme Siège social Numéro 35E Rue Avenue John F.

Tyto typy korupčních obchodních aktivit se vztahují na kohokoli, s kým spolupracujeme nebo chceme spolupracovat. Naše pověst integrity je důležitější než potenciální zisky, které lze získat nepatřičným jednáním s jinými osobami a organizacemi. Obraťte se na svého právního partnera, aby vyžádal náležitou hloubkovou kontrolu a zajistil, že jste obdrželi písemný souhlas před zahájením spolupráce s jakýmkoli zástupcem nebo třetí stranou.

ELECTRICAL PARTS MANUFACTURER H E A V Y D U T Y C O N N E C T O R S A N D A C C E S S O R I E S • Reduce material rematching and rejection through more efficient pre-testing • Improve processing efficiencies and color consistency in highly FR-filled and high-temperature resins • Achieve regulatory compliance across multiple resin families • Gain better supply chain control to manage scarcity of key engineering resins and changing resin producers • Offered eight UL 94-recognized sites in U.S. and Canada that perform comprehensive analytical, physical and mechanical testing • Provided increased speed to market and expedited design timelines for new products using existing standardized and pre- approved color palettes • Ensured regulatory compliance and security of supply OnColor™ UL 94 Colorants KEY REQUIREMENTS WHY AVIENT AVIENT SOLUTION QUALITY + SPEED TO MARKET LEARN MORE © 2023, Avient Corporation, All Rights Reserved https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/oncolor-ul94-colorants

Glucose Monitoring App Snapshot draft MEDICAL DEVICE OEM C O N T I N U O U S G L U C O S E M O N I T O R I N G S Y S T E M • Adapt to strict processing requirements of a secondary operation put in place to manufacture a new device model • Meet material size and thickness requirements while achieving desired color target • Overcome material unpredictability and sensitivity to heat, light and moisture • Minimize impact of supply chain instability and changes • Offered support for processing under low pressure conditions and at every stage of manufacturing • Performed extensive R&D work to consistently deliver the customer’s color target of a hard-to-achieve light gray • Effectively addressed all material challenges and sensitivities • Provided regular ‘summaries of understanding’ to keep up with changing forecasts and ordering patterns Mevopur™ Pre-color Formulation KEY REQUIREMENTS WHY AVIENT?

MEDICAL EQUIPMENT MANUFACTURER S U R G I C A L X - R A Y G L A S S E S • Replace lead while providing uniform shielding performance • Radiation shielding up to 140KeV • Improve glasses design • Compliance with Radiation Protection Regulation: Adult eye exposure must be below 20 mSv per calendar year • Conducted extensive testing to ensure comparable and uniform shielding performance • Improved geometric flexibility • Lowered shielding component costs 30-50% by eliminating machining and assembly steps (associated with lead) • Reduced weight of the glasses and enabled a more ergonomic design • Eliminated disposal concerns associated with lead Trilliant™ XR Lead Replacement Thermoplastics KEY REQUIREMENTS WHY AVIENT?

Wire & cable manufacturer WIRE & CABLE MANUFACTURER A E R O N A U T I C D A T A T R A N S M I S S I O N C A B L E S • Permanent contrast marking meeting aerospace industry standards SAE AS4373F and EN-3475-706 • Benign marking that, compared to infrared (IR) laser marking, will not damage the jacket surface • Elevated temperature performance in corrosive environments, maintaining dielectric properties under continuous service • No vital optical fiber or data transmission cable interference • Demonstrated fluorinated ethylene propylene (FEP) application expertise incorporating laser marks • Provided formulation expertise in PTFE alternatives • Delivered a high-quality product with no clumping during the extrusion process • Offered a proven array of specific aeronautic colors • Provided commercial, technical, and operational support KEY REQUIREMENTS APPEARANCE + PERFORMANCE WHY AVIENT?

MEDICAL EQUIPMENT MANUFACTURER C L O S E D S Y S T E M D R U G T R A N S F E R D E V I C E • A new material for a seal inside the next generation of closed system drug transfer device • Compliance with stringent regulatory standards: • Biocompatibility to ISO10993 • USP VI compliance • Provided regulatory support services and expertise throughout extensive medical approval process • Provided a custom formulation compliant with the highest healthcare regulatory standards • Enabled material to be manufactured and shipped globally Custom Versalloy™ HC 9220-90 Formulation KEY REQUIREMENTS WHY AVIENT?

Microsoft PowerPoint - AVNT Mar 2022 Presentation AVIENT CORPORATION I N V E S T O R M E E T I N G S (NYSE: AVNT) M A R C H 2 0 2 2 DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. D is t. ) K W R P P G F U L R P M A V Y F M C H U N H X L S C L E C L E M N C E A S H Source: Peer data per Bloomberg market data as of February 15, 2022. OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 5.4 8.5 10.1 10.0 15.7 15.0 14.2 12.7 10.2 25.0 19.7 17.7 13.2 12.3 10.0 9.9 8.9 8.5 8.3 6.6 A vi en t (2 01 1) A vi en t (2 01 6) A vi en t (2 02 1) A vi en t (T o da y) R P M K W R P P G A V Y F U L A L B E C L H X L A S H F M C B N R E M N U N V R C E S C L H U N Historic Multiple SUMMARY: WHY INVEST IN AVIENT?

Microsoft PowerPoint - AVNT Q2 2021 Earnings Presentation - Website AVIENT CORPORATION S E C O N D Q U A R T E R 2 0 2 1 R E S U LT S (NYSE: AVNT) J U LY 3 0 , 2 0 2 1 DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. D is t. ) K W R P P G A V Y F U L R P M G C P H X L F M C H U N IF F E C L A S H K R A E M N C E S C L A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of July 28, 2021 Avient reflects 2021 estimated revenue of $4,650M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 25 Avient reflects 2021 estimated EBITDA of $580M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 9.5 18.5 15.1 15.1 14.0 11.0 10.4 29.5 28.2 23.9 18.7 12.4 12.2 11.1 9.3 9.2 9.2 7.6 7.6 6.0 A vi en t K W R P P G A V Y R P M F U L G C P A L B H X L E C L IF F F M C B N R A S H S C L E M N U N V R K R A C E H U N Median: 11.1xMedian: 14.6x SUMMARY: WHY INVEST IN AVIENT?

Microsoft PowerPoint - Avient Q1 2021 Earnings - Final (For Print) AVIENT CORPORATION F I R S T Q U A R T E R 2 0 2 1 R E S U LT S (NYSE: AVNT) A P R I L 3 0 , 2 0 2 1 DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. D is t. ) K W R R P M P P G A V Y F U L G C P IF F H X L F M C F O E H U N E C L K R A E M N A S H C E S C L G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of April 27, 2021 Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 20 Avient reflects 2021 estimated EBITDA of $560M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 10.2 17.7 16.0 14.9 14.6 11.6 11.1 26.7 24.0 22.8 14.3 12.7 11.5 11.2 11.1 11.0 10.3 10.1 9.5 9.4 8.3 7.0 A vi en t K W R A V Y R P M P P G G C P F U L A L B H X L E C L IF F F M C B N R A S H G R A F O E S C L E M N U N V R C E K R A H U N Median: 11.1xMedian: 14.8x SUMMARY: WHY INVEST IN AVIENT?